Effect of intraamniotic @entity619 administration on intestinal absorption in a @entity95 XXXX model.

@entity1 @entity1944 @entity95 @entity23252 @entity619 @entity134 @entity6675 @entity24575
@entity1 with @entity6675 experience delayed intestinal motility and absorption for several weeks after birth. This @entity1944 is believed to occur primarily in the third trimester and to be largely caused by the prolonged exposure of the intestine to amniotic fluid. Previous studies have shown that prenatal @entity134 administration will enhance mucosal disaccharidase activity and nutrient uptake. The present study evaluates the effects of @entity619 on intestinal function in a @entity95 fetal @entity6675 model. Thirty-four fetuses from 10 New Zealand white @entity95 were divided into three groups: (1) @entity6675 group (GSC, n = 10), @entity6675 was created on gestational day (GD) 24 (term = 31 to 33 days); (2) @entity619 group ( @entity24575 , n = 10), after the creation of @entity6675 , a small osmotic pump was placed into the @entity95 doe for @entity619 infusion into the fetal amniotic cavity for 7 days (0.2 microgram/g/d); (3) normal group (NF, n = 10), unoperated littermates from the GSC group. There were no maternal deaths, and fetal survival rate was 85%. The fetal small intestinal disaccharidase enzyme, @entity23252 (UE/g protein), was markedly decreased in GSC fetuses. It was increased 70% in the @entity24575 group but lower than in normal fetuses (GSC = 10.0 +/- 1.6; @entity24575 = 17.3 +/- 1.6 [ @entity24575 versus GSC, P < .05]; NF = 48.0 +/- 6.7). Maltase activity in the @entity24575 group was significantly increased (GSC = 7.2 +/- 1.1; @entity24575 = 13.9 +/- 1.8 [ @entity24575 versus GSC, P < .05]; NF = 12.2 +/- 1.3).(ABSTRACT TRUNCATED AT 250 WORDS)
